Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
ADX-102 Ophthalmic Drops (0.5%)
Aldeyra Therapeutics
Conjunctivitis, Allergic
1 trial -
ADX-102 Ophthalmic Solution (0.5%)
Aldeyra Therapeutics
Dry Eye Syndromes
1 trial -
ADX-2191
Aldeyra Therapeutics
Retinitis Pigmentosa
1 trial -
ADX-629
Aldeyra Therapeutics
Chronic Cough
1 trial -
ADX-629
Aldeyra Therapeutics
Covid19
1 trial -
ADX-629
Aldeyra Therapeutics
Ethanol Intoxication
1 trial -
ADX-629
Aldeyra Therapeutics
Atopic Asthma
1 trial -
ADX-629
Aldeyra Therapeutics
Alcohol Hepatitis
1 trial -
ADX-629
Aldeyra Therapeutics
Nephrotic Syndrome
1 trial -
ADX-629
Aldeyra Therapeutics
Plaque Psoriasis
1 trial -
ADX-629 (Open-label)
Aldeyra Therapeutics
Atopic Dermatitis
1 trial -
ADX10059
Addex Therapeutics
Gastroesophageal Reflux
2 trials -
ADX10059
Addex Therapeutics
Migraine
1 trial -
ADX48621
Addex Therapeutics
Parkinson's Disease
1 trial -
AEVI-001
Avalo Therapeutics
Attention Deficit Hyperactivity Disorder
2 trials -
AFM13
Artiva Biotherapeutics
Relapsed or Refractory Hodgkin Lymphoma
1 trial -
AG-120
Agios Netherlands B.V.
Chondrosarcoma
1 trial -
AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung
The George Institute
Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation
1 trial -
AG-348
Agios Netherlands B.V.
Thalassemia
1 trial -
AG10
BridgeBio Oncology Therapeutics
Familial ATTR-CM (ATTRm-CM, or FAC)
1 trial -
AG10
BridgeBio Oncology Therapeutics
Amyloid Cardiomyopathy
1 trial -
AGMB-129
Agomab Therapeutics NV
Fibrostenotic Crohn's Disease
2 trials -
AIR DNase™
Protalix BioTherapeutics
Cystic Fibrosis
1 trial -
AK104, nab-paclitaxel, carboplatin
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources